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Antisense oligonucleotides (ASOs) can suppress the expression of a target gene by cleaving pre-mRNA
and/or mature mRNA via RNase H1. Following the initial endonucleolytic cleavage by RNase H1, the
target RNAs are degraded by a mechanism that is poorly understood. To better understand this degra-
dation pathway, we depleted the expression of two major 50 to 30 exoribonucleases (XRNs), named XRN1
and XRN2, and analyzed the levels of 30 fragments of the target RNAs in vitro. We found that the 30
fragments of target pre-mRNA generated by ASO were almost completely degraded from their 50 ends by
nuclear XRN2 after RNase H1-mediated cleavage, whereas the 30 fragments of mature mRNA were
partially degraded by XRN2. In contrast to ASO, small interference RNA (siRNA) could reduce the
expression level of only mature mRNA, and the 30 fragment was degraded by cytoplasmic XRN1. Our
ﬁndings indicate that the RNAs targeted by RNase H1-dependent ASO are rapidly degraded in the nu-
cleus, contrary to the cytoplasmic degradation pathway mediated by siRNA.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction There are twomajor eukaryotic 50 to 30 exoribonucleases (XRNs),Antisense oligonucleotides (ASOs) have been widely used as
laboratory tools and therapeutic agents because of their potent and
speciﬁc ability to inhibit the expression of a target gene in vitro and
in vivo [1e3]. It was ﬁrst reported over 35 years ago that a short
synthetic oligodeoxynucleotide can inhibit the replication and
protein expression of Rous sarcoma virus [4,5]. In the early years of
this technology, the inhibition activity of ASO was thought to be
caused by a steric blocking effect upon hybridization to target RNA.
Subsequently, it was reported that target RNAs are cleaved by
RNase H at the site of the RNA/DNA heteroduplex [6]. Once ASOs
bind via Watson-Crick hybridization to target RNAs, RNase H1 is
recruited and hydrolyzes RNA in RNA/DNA hybrids through its
endonucleolytic activity. Following endonucleolytic cleavage by
RNase H1, the target RNA fragments immediately disappear, sug-
gesting that they are rapidly degraded by intracellular nucleases
[7], although the degradation mechanism is not understood in
detail. In addition, since RNase H1 mainly resides in the cellular
nucleus and mitochondria [8], both pre-mRNA and mature mRNA
are likely targets for ASOs, but it is unknown if they are degraded by
the same degradation pathway.).
r Inc. This is an open access articlXRN1 and XRN2. XRN1 is primarily localized in the cytoplasm and
has important roles in mRNA turnover and degradation, and it
degrades decapped mRNA. In addition, various noncoding RNA
transcripts, such as long non-coding RNA (lncRNA), small nucleolar
RNA (snoRNA), and aberrant tRNA, are degraded by XRN1 [9]. In
Drosophila cells, the 30 fragments of target mRNA generated by
siRNAs are decomposed by XRN1 after endonucleolytic cleavage by
AGO2 [10]. In contrast, XRN2 is an evolutionarily conserved XRN
related to XRN1, but is predominantly present in the nucleus. XRN2
has an important function inmRNA transcription termination. After
RNA polymerase II transcribes a poly (A) signal, the transcript is
cleaved and the 50 fragment is polyadenylated. Although RNA po-
lymerase II continues transcription beyond the poly (A) signal,
XRN2 enters at the cleavage site and degrades the 30 transcript until
it dissociates RNA polymerase II from the DNA template. XRN2 also
plays crucial roles in the maturation and quality control of several
classes of RNA such as rRNA, snoRNA, and pre-mRNA [9,11].
The aim of this study was to better understand the degradation
mechanism of RNAs targeted by ASOs, and thus we modiﬁed the
expression of XRN1 and XRN2 to analyze the fate of 30 fragment of
the target pre-mRNA or mature mRNA generated by RNase H1-
dependent ASO. We also investigated the XRN responsible for the
degradation of target RNA mediated by siRNA in mammalian cells.
We found that the 30 fragments of target RNA generated by ASOs
are rapidly degraded from their 50 ends by nuclear XRN2, unlike in
the case with siRNA. Moreover, our data suggest that there may bee under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mediated by RNase H1 and XRN2.2. Materials and methods
2.1. siRNAs and antisense oligonucleotides
ApoB-ASO reported previously by Straarup et al. [2] and Her3-
ASO reported previously by Zhang et al. [12] were prepared and
used in this study. These ASOs were phosphorothioated and
modiﬁed with locked nucleic acid (LNA) (also known as 20-O,40-C-
methylene-bridged nucleic acid (20,40-BNA)) [13,14]. The sequences
of the ASOs are shown in Table S1. These ASOs were synthesized
and puriﬁed by Gene Design, Inc. (Osaka, Japan). XRN1 siRNA, XRN2
siRNA, RNase H1 siRNA, ApoB siRNA, and negative control (NC)
siRNA with a medium GC content, were obtained from Invitrogen
(Carlsbad, CA, USA) as Stealth RNAi siRNAs. The sequences of the
siRNAs used in this study are shown in Table S2.2.2. Cell culture
Huh-7 (a human hepatoma cell line) and HepG2 (a human
hepatoblastoma cell line) cells were obtained from the Japanese
Collection of Research Bioresources (JCRB; Osaka, Japan). These
cell lines were maintained at 37 C and 5% CO2 in Dulbecco's
Modiﬁed Eagle's Medium (DMEM; Nacalai Tesque, Kyoto, Japan)
supplemented with 10% heat-inactivated fetal bovine serum
(FBS) and antibiotics/antimycotics (SigmaeAldrich, St. Louis, MO,
USA).Fig. 1. Effects of RNase H1 siRNA on the potency of ApoB-ASO. (A) Huh-7 cells were trans
assessed by western blot and qRT-PCR. b-actin was used as a loading control for western blot
These values were set to 100% in the untreated control (UTC). (B, C) Following siRNA treatme
mRNA (B) and pre-mRNA (C) was analyzed by qRT-PCR. The bar graph shows mean ± SD
untreated control.2.3. Transfections with siRNA and ASO
Huh-7 or HepG2 cells were seeded and transfected in 96-well
plates (Corning; Corning, NY, USA). After seeding Huh-7 cells at
7.5  103 cells/well or HepG2 cells at 1.5  104 cells/well, the cells
were reverse transfected with 20 nM siRNA for Huh-7 cells or
40 nM for HepG2 cells using Lipofectamine 3000 (Invitrogen) ac-
cording to the manufacturer's protocol. The medium was changed
the following day to fresh 10% FBS/DMEM. After 24 h, cells were
transfected with 100 nM ApoB-ASO or Her3-ASO, or 20 nM ApoB
siRNA, using Lipofectamine 3000 (Invitrogen).
2.4. Quantitative reverse transcription-polymerase chain reaction
Twenty four hours after the second transfection, total RNA was
extracted using a CellAmp Direct RNA Prep Kit (TaKaRa Bio Inc.,
Shiga, Japan) according to the manufacturer's instructions. Quan-
titative reverse transcription-polymerase chain reaction (qRT-PCR)
was performed using a One Step SYBR PrimeScript PLUS RT-PCR Kit
(Takara Bio Inc.) and analyzed with a StepOnePlus system (Applied
Biosystems; Foster City, CA, USA). The sequences of the primer set
are shown in Table S3. The expression levels of the target RNAwere
quantitated in at least three independent experiments and
normalized to those of GAPDH.
2.5. Western blot
Total cellular protein was prepared by cell lysis in radio-
immunoprecipitation assay (RIPA) buffer (SigmaeAldrich) with
Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN, USA).
Total protein concentrations were determined with a BCA proteinfected with RNase H1 or NC siRNA and the expression level of cellular RNase H1 was
. The level of RNase H1 mRNAwas quantitated and normalized to that of GAPDH mRNA.
nt, cells were transfected with ApoB-ASO for 24 h. The expression level of ApoB mature
(n ¼ 3). *p < 0.05, **p < 0.005 determined by Student's t-test compared to the siRNA
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cording to manufacturer's protocol. Aliquots corresponding to 6 mg
total protein were separated by SDS-polyacrylamide gel electro-
phoresis (5e20% gradient gel) and blotted onto PVDF membranes.
The membranes were blocked for 1 h in Blocking One (Nacalai
Tesque) and incubated overnight at 4 C in Tris-buffered saline and
0.1% Tween 20 (TBS-T) containing 5% bovine serum albumin and
monoclonal mouse anti-XRN1 antibody (1:100) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), monoclonal rabbit anti-XRN2
antibody (1:1000) (Cell Signaling Technology, Danvers, MA, USA),
monoclonal rabbit anti-RNase H1 antibody (1:1000) (ProteinTech,
Chicago, IL, USA), or for 1 h at room temperature in Blocking One
containing monoclonal mouse anti-b-actin (1:1000) (Sigma-
eAldrich). Subsequently, the membranes were incubated for 1 h
with horseradish peroxidase (HRP)-conjugated antibodies (1:3000)
(Amersham Biosciences, Buckinghamshire, UK). The blots were
visualized using an ECL Prime kit (Amersham Biosciences) and
ImageQuant LAS 4000 (Fuji Film, Tokyo, Japan).2.6. 50 Rapid ampliﬁcation of cDNA ends
To identify the 30 RNA fragments generated by RNase H1-
mediated endonucleolytic cleavage, 50 rapid ampliﬁcation of the
cDNA ends (50 RACE) was performed using a GeneRacer kit (Invi-
trogen) according to the manufacturer's instructions. Brieﬂy, the
GeneRacer RNA oligo was ligated to the 50-end of the 30 RNA frag-
ments using T4 ligase. The ligated RNA was reverse transcribed by
SuperScript III reverse transcriptase and the randomprimer. For the
ﬁrst ampliﬁcation of 50 RACE cDNA, touchdown PCR was performedFig. 2. Effects of XRN depletion on the degradation of the 30 fragments of ApoB mature mR
expression levels of cellular XRN1 and XRN2 were assessed by western blot and qRT-PCR. T
mRNA. These values were set to 100% in the untreated control (UTC). (B) Schematic represe
qRT-PCR analysis. Exon 26 is targeted by ApoB-ASO and ApoB siRNA. The forward primer wa
ApoB mature mRNA and 30 cleavage product. The forward primer was designed on exon 28
and 30 cleavage product. Each primer set ampliﬁed a single product of the expected size. (C
24 h. The levels of 30 fragment (30 frag.) and full-length ApoB mature mRNA (left panel)
Following XRN1 or XRN2 siRNA treatment, cells were transfected with ApoB siRNA for 24 h.
pre-mRNA (right panel) generated by ApoB siRNA were assessed by qRT-PCR. The bar gra
compared to the siRNA untreated control.using the GeneRacer 50 primer and the ApoB pre-mRNA speciﬁc
primer 50-ACTGGGAGAATTCTATCCTAACCAGAT-30 with initial
denaturation (5 min at 98 C), three cycles of annealing at 72 C,
three cycles at 69 C, three cycles at 66 C, three cycles at 63 C, and
20 cycles at 60 C. Each annealing was followed by a 2 min primer
extension at 72 C and a 10 s denaturation at 98 C. The ﬁnal
extension time at 72 C was 7 min. The second ampliﬁcation was
performed for an additional 25 cycles with the GeneRacer 50 nested
primer and the second ApoB pre-mRNA speciﬁc primer 50-TCTAG-
GAGAGGAGGCAGGATATTTCT-30. 50 RACE products were visualized
on 1% agarose gels stained with ethidium bromide. To determine
the cleavage sites, the PCR product was cloned into p-GEM T easy
vector (Promega, Madison, WI, USA) and sequenced.
2.7. Statistical analyses
Statistical comparisons of results were performed by Student's
t-tests.
3. Results
3.1. Analysis of the expression level of target RNA after RNase H1
knockdown
To examine whether the reduction of target mature mRNA and
pre-mRNA levels caused by the ASO was deﬁnitely through RNase
H1 cleavage, we ﬁrst investigated whether depletion of RNase H1
expression prevents ASO-mediated degradation of these tran-
scripts. Huh-7 cells were treated with RNase H1 siRNAs, and afterNA or pre-mRNA. (A) Huh-7 cells were transfected with XRN1 or XRN2 siRNA and the
he level of XRN1 and XRN2 mRNA was quantitated and normalized to that of GAPDH
ntation of ApoB transcripts, oligonucleotides (lines) and primer sets (arrowheads) for
s designed on exon 28 and the reverse primer was designed on exon 29 to detect intact
and the reverse primer was designed on intron 28 to detect the intact ApoB pre-mRNA
) Following XRN1 or XRN2 siRNA treatment, cells were transfected with ApoB-ASO for
and pre-mRNA (right panel) generated by ApoB-ASO were assessed by qRT-PCR. (D)
The levels of 30 fragment (30 frag.) and full-length ApoB mature mRNA (left panel) and
ph shows mean ± SD (n ¼ 3). *p < 0.05, **p < 0.005 determined by Student's t-test
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expression levels of ApoB transcripts were analyzed 24 h after
transfectionwith ASO. RNase H1 siRNA promoted an approximately
80% reduction in RNase H1 mRNA and protein levels (Fig. 1A).
Treatment with ApoB-ASO reduced the expression levels of ApoB
mature mRNA by approximately 90% without pretreatment of
RNase H1 siRNA, while RNase H1 depletion attenuated the knock-
down effect of ApoB-ASO by approximately 75% (Fig. 1B). Consid-
ering that RNase H1 is mainly located in the nucleus and
mitochondria [8], and also that ASOs targeting sites in introns can
promote target reduction [15], it is likely that pre-mRNA is targeted
by ASO as well. Therefore, we investigated the expression level of
ApoB pre-mRNA in the same cell lysate. ApoB-ASO resulted in
approximately 60% reduction in ApoB pre-mRNA without pre-
treatment of RNase H1 siRNA, while the knockdown activity of this
ASO was almost entirely ablated in RNase H1 depleted cells
(Fig. 1C). These results suggest that the reduction of ApoB pre-
mRNA is almost completely due to direct cleavage by RNase H1,
while the reduction of ApoB mature mRNA is due not only to pre-
mRNA reduction, but also to direct cleavage of mature mRNA by
RNase H1. Further, these data also suggest that there may be
another degradation pathway leading to decreased mature mRNA
because ApoB-ASO remained active at the level of mature mRNA,
even though cellular RNase H1 was reduced by more than 80%.Fig. 3. Further evaluation of the knockdown effect of XRN2. (A) Huh-7 cells were transfected
by western blot and qRT-PCR. The level of XRN2 mRNA was quantitated and normalized to t
Following siRNA treatment, cells were transfected with ApoB-ASO for 24 h. The levels of 30 f
panel) generated by ApoB-ASO were assessed by qRT-PCR. (C) HepG2 cells were transfected w
western blot and qRT-PCR. The level of XRN2 mRNA was quantitated and normalized to th
Following siRNA treatment, cells were transfected with Her3-ASO for 24 h. The levels of 30 f
panel) generated by Her3-ASO were assessed by qRT-PCR with primer sets downstream of
***p < 0.005 determined by Student's t-test compared to the siRNA untreated control.3.2. Quantiﬁcation of the 30 fragments of target RNA generated by
RNase H1-dependent ASO
Since the knockdown effect of ApoB-ASO was mediated by
RNase H1, 50 and 30 degradation fragments of target RNAs are
thought to be generated after endonucleolytic cleavage by RNase
H1. However, following initial endonucleolytic cleavage by RNase
H1, the transcripts targeted by ASOs are degraded by a poorly un-
derstood mechanism. XRN1 and XRN2 are two major 50 to 30
exoribonucleases for RNA processing in mammalian cells [9]. To
investigate whether XRN1 or XRN2 is responsible for the degra-
dation of the 30 fragment generated by RNase H1 cleavage, we
depleted these exonucleases in Huh-7 cells. XRN1 or XRN2 siRNA
promoted approximately 60e90% reduction in target mRNA and
protein levels (Fig. 2A). After siRNA treatment, ApoB-ASO was
transfected into the cells and the expression levels of ApoB mature
mRNA or pre-mRNA were analyzed 24 h later. In addition, we used
ApoB siRNA instead of ApoB-ASO to compare the degradation
pathway involving ASO or siRNA. Speciﬁc primer sets were
designed in the 30 downstream of the ApoB-ASO or ApoB siRNA
target region on ApoB mature mRNA or pre-mRNA for qRT-PCR
(Fig. 2B). These primer sets were used for ampliﬁcation of both
intact transcripts and 30 cleavage fragments. When cells were
treated with ApoB-ASO, depletion of XRN1 did not result in accu-
mulation of the 30 fragment of ApoB mature mRNA and pre-mRNA.with each XRN2 siRNA or NC siRNA. The expression level of cellular XRN2 was assessed
hat of GAPDH mRNA. These values were set to 100% in the untreated control (UTC). (B)
ragment (30 frag.) and full-length ApoB mature mRNA (left panel) and pre-mRNA (right
ith XRN2 siRNA or NC siRNA and the expression level of cellular XRN2 was assessed by
at of GAPDH mRNA. These values were set to 100% in the untreated control (UTC). (D)
ragment (30 frag.) and full-length Her3 mature mRNA (left panel) and pre-mRNA (right
the ASO binding site. The bar graph shows mean ± SD (n ¼ 3). *p < 0.05, **p < 0.01,
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change the levels of the 30 fragment of ApoB mature mRNA, but did
show a slight tendency to increase (p ¼ 0.062). Interestingly,
depletion of XRN2 led to signiﬁcant accumulation of the 30 frag-
ment of ApoB pre-mRNA (Fig. 2C). In contrast, when cells were
treated with ApoB siRNA, only ApoB mature mRNA was reduced,
and depletion of XRN1 led to accumulation of the 30 fragment of
ApoB mature mRNA (Fig. 2D).3.3. Further evaluation of the knockdown effect of XRN2
We performed two additional experiments to support our
ﬁnding that the RNase H1-mediated fragment of ApoB transcripts
appears to accumulate by depletion of XRN2. Different sequences of
XRN2 siRNA were used and the 30 fragment of ApoB transcripts in
Huh-7 cells was analyzed. We conﬁrmed that all of the XRN2 siR-
NAs, including the preceding siRNA (XRN2 si1), resulted in more
than 90% reduction of both mRNA and protein (Fig. 3A). Depletion
of XRN2 resulted in signiﬁcant accumulation of the 30 fragment of
ApoB pre-mRNA when cells were treated with any of the XRN2
siRNAs. Additionally, the levels of the 30 fragment of mature mRNA
slightly but signiﬁcantly changed upon treatment with any XRN2
siRNA (Fig. 3B). These results proved that both pre-mRNA and
mature mRNA are degraded by XRN2, and this change is not caused
by off-target effects of a speciﬁc sequence of XRN2 siRNA. To
investigate whether XRN2-mediated degradation is a general
pathway for target RNAs by RNase H1-dependent ASO, we con-
ducted a similar experiment using a different target gene (Her3)
and cell line (HepG2). Speciﬁc primer sets were designed in the 30
downstream of the Her3-ASO target region on Her3 mature mRNAFig. 4. 50 RACE analysis of the 30 fragments generated by RNase H1-mediated cleavage. (A) Sc
site and the primers used for PCR ampliﬁcation of the cleavage fragment. GR5; GeneRacer
primer; GSP2; ApoB pre-mRNA speciﬁc nested primer. (B) Agarose gel visualizing 50 RACE PC
GSP2. (C) The sequence of ApoB pre-mRNA containing the ApoB-ASO binding site (under
individual clones from 50 RACE derived from XRN2-depleted cells. The numbers above the
chromatograph containing the main cleavage site is illustrated in the lower panel. (D) A sche
siRNA (left panel) and ASO (right panel).or pre-mRNA for qRT-PCR (Fig. S1). HepG2 cells were treated with
XRN2 or NC siRNA. After 48 h, Her3-ASO was transfected into the
cells and the expression levels of Her3 mature mRNA and pre-
mRNA were analyzed by qRT-PCR. XRN2 siRNA promoted greater
than 90% reduction in mRNA and protein levels (Fig. 3C) and
depletion of XRN2 led to the signiﬁcant accumulation of the 30
fragment of both Her3 mature mRNA and pre-mRNA (Fig. 3D).
These ﬁndings indicate that XRN2 completely degrades the 30
fragment of pre-mRNA and at least partly degrades that of mature
mRNA targeted by ASO in any target and cell line.3.4. 50 RACE analysis of the 30 RNA fragments generated by RNase
H1-mediated cleavage
To identify the 30 RNA fragments generated by RNase H1-
mediated endonucleolytic cleavage, 50 rapid ampliﬁcation of
cDNA ends (50 RACE) was performed on RNA from cells transfected
with ApoB-ASO (Fig. 4A). 50RACE products were detected in cells
treated with ApoB-ASO, and pretreatment with XRN2 siRNA
increased the 50RACE band intensity compared to pretreatment
with NC siRNA (Fig. 4B). The 50 end of RNase H1 cleaved products in
XRN2-depleted cells were conﬁrmed by sequencing 18 individual
clones from 50RACE; the results showed that all the 50 ends of 30
fragments are positioned within the binding site of ApoB-ASO
(Fig. 4C). Human RNase H1 preferentially cleaves the heterodu-
plex substrate between 7 and 12 nucleotides from the 50-RNAe30-
DNA terminus of the duplex [16]. Our results suggest that XRN2 acts
as a primary 50 exonuclease following endonucleolytic cleavage by
RNase H1 because the cutting sites of RNase H1 are retained in
XRN2-depleted cells.hematic representation of ApoB pre-mRNA, illustrating the location of the ASO cleavage
50 primer, GRN5; GeneRacer 50 nested primer; GSP1; ApoB pre-mRNA speciﬁc reverse
R ampliﬁcation products after siRNA and ASO treatment using the primer set GRN5 and
lined) is illustrated. The arrows indicate the 50 ends as determined by sequencing of
arrows indicate the number of clones sequenced with that cleavage site. The sequence
matic diagram for the degradation pathway of 30 fragments of target RNA generated by
S.-I. Hori et al. / Biochemical and Biophysical Research Communications 464 (2015) 506e511 5114. Discussion
siRNA degrades the target RNA via intracellular endonuclease
AGO2. Orban et al. reported that, following endonucleolytic cleav-
age by AGO2, the 30 fragment of target RNA generated by siRNA is
degraded by cytoplasmic 50 to 30 exoribonuclease XRN1 in
Drosophila cells [10]. We likewise showed that depletion of XRN1
speciﬁcally results in accumulation of the 30 fragment of target
mRNA generated by siRNA in mammalian cells, consistent with the
fact that siRNA can operate in the cytoplasm via RISC complexes
containing AGO2. ASO likely operates through two degradation
pathways. In one pathway, the fragment of target RNA is exported
to the cytosol after cleavage by RNase H1 in the nucleus and is then
degraded by the same pathway as siRNA. In the other, the fragment
of target RNA is degraded in the nucleus. Both possibilities were
examined by focusing on two 50 to 30 exoribonucleases, cytoplasmic
XRN1, and nuclear XRN2. We found that depletion of XRN2 spe-
ciﬁcally results in accumulation of the 30 fragment of target RNA
generated by RNase H1-dependent ASO, indicating that the frag-
ment cleaved by RNase H1-dependent ASO is degraded by XRN2 in
the nucleus and identiﬁes a new function of XRN2.
Our ﬁndings show that the cutting or degradation of pre-mRNA
is almost completely suppressed by depletion of RNase H1 or XRN2,
suggesting that pre-mRNAs are targeted by RNase H1 and that their
fragments are degraded by XRN2 in the nucleus. This conclusion is
compatible with the fact that ASO can induce exon skipping by
targeting pre-mRNA, and ASO targeting the intron can cleave pre-
mRNA via RNase H1 in the nucleus [17,18]. On the other hand,
since the cutting and degradation of mature mRNA was slightly
inhibited by depletion of RNase H1 or XRN2, ASO and RNase H1
may also interact with mature mRNA and this mature mRNA is at
least partly degraded by XRN2. Further, our data suggest that there
may be another degradation mechanism that contributes to the
activity of ASO targeting mature mRNA because ApoB-ASO was still
active at the level of mature mRNA, even though cellular RNase H1
was reduced by more than 80%. Previously, Wu et al. reported
another RNase Hwhichmay play a role in the activity of ASOs [7]. In
addition, since mature mRNA is believed to be present in both the
nucleus and cytoplasm, it would be interesting to know whether
there are different degradation pathways depending on the sub-
cellular localization of the mRNA. We are currently investigating
this possibility. A proposed mechanism for the degradation
pathway of target RNA generated by siRNA and ASO is illustrated in
Fig. 4D.
In this study, we focused on the 30 fragment of target RNAs
generated by RNase H1-dependent ASO. It has also been reported
that the 50 fragment of target RNA generated by siRNA can be
degraded by the exosome complex present in the cytoplasm of
Drosophila cells [10]. Exosome complex has been reported to also be
in the nucleus [19]. Further investigation is needed to reveal how
the 50 fragments of RNA cleaved by RNase H1-dependent ASO are
degraded inmammalian cells. In conclusion, we revealed that the 30
fragments of target RNAs generated by RNase H1-dependent ASO
are rapidly degraded from their 50 ends by XRN2 in the nucleus, in
contrast to the degradation pathway of siRNA. This ﬁndingwill help
shed light on the poorly understood degradation mechanisms of
RNAs targeted by ASO.
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